Uncategorized
Sygnature Discovery appoints new Head of In Vivo Pharmacology
CRO Sygnature Discovery has announced the appointment of Susanne Back as Head of In Vivo Pharmacology.
Back has 20 years of in vivo pharmacology experience across academia and industry, including senior scientific and leadership roles at Orion Pharma and Charles River. She will lead one of Sygnature’s in vivo pharmacology teams, delivering the company’s in vivo strategies that it says will support informed decision-making across drug discovery programmes.
Back will be responsible for the scientific and operational leadership of the team, including resource planning, workflow optimisation, and the continued development of innovative and competitive in vivo capabilities.
“I was particularly attracted to Sygnature because of its world-leading integrated drug discovery expertise and the calibre of its scientific community,” Back said.
“The co-located, multidisciplinary environment creates a truly collaborative setting where complex discovery challenges can be addressed efficiently. I am looking forward to working closely with colleagues and clients to ensure we continue to deliver translational in vivo data that accelerates drug discovery programmes.”
The appointment follows Sygnature’s recent strategic brand launch, aiming to reinforce its position as a global drug discovery partner.
The post Sygnature Discovery appoints new Head of In Vivo Pharmacology appeared first on Drug Discovery World (DDW).
Uncategorized
STAT+: Is there a pharma mega-merger in the making?
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Hiya, and welcome back to The Readout.
Today, we’re getting ready for the FDA’s upcoming decision on Moderna’s mRNA flu shot, and see both a revived fight over 340B rebates and fresh legal scrutiny for Lilly’s insulin pricing.
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Hiya, and welcome back to The Readout.
Today, we’re getting ready for the FDA’s upcoming decision on Moderna’s mRNA flu shot, and see both a revived fight over 340B rebates and fresh legal scrutiny for Lilly’s insulin pricing.
BioNTech’s leadership transition was announced earlier this year, with CEO Ugur Sahin and CMO Özlem Türeci leaving to start a new mRNA company. Guido Oelkers of Swedish Orphan Biovitrum AB will take over as CEO in early 2027.
Uncategorized
STAT+: Sandoz to pay $478.5 million to settle price-fixing allegations in long-running battle with states
Sandoz agreed to pay $478.5 million to settle allegations by dozens of states and resellers of medicines that the company engaged in a widespread conspiracy to artificially inflate and manipulate prices of generic drugs and harmed consumers by reducing competition.
Under one settlement, the company agreed to pay $400 million over seven years starting in 2027 to resolve all remaining claims by U.S. states in three pending cases and make an additional payment of about $50 million to states that settled earlier. Another $28.5 million will be paid to resolve all remaining class-action litigation brought by indirect resellers. Sandoz did not admit to any wrongdoing.
The agreement marks the latest settlement in a long-running battle between numerous states and many of the largest players in the generic drug industry, which were accused of fixing prices for their medicines. Previously, Glenmark Pharmaceuticals, Lannett, Bausch, Apotex, and Heritage Pharmaceuticals collectively settled lawsuits for nearly $98 million.
Sandoz agreed to pay $478.5 million to settle allegations by dozens of states and resellers of medicines that the company engaged in a widespread conspiracy to artificially inflate and manipulate prices of generic drugs and harmed consumers by reducing competition.
Under one settlement, the company agreed to pay $400 million over seven years starting in 2027 to resolve all remaining claims by U.S. states in three pending cases and make an additional payment of about $50 million to states that settled earlier. Another $28.5 million will be paid to resolve all remaining class-action litigation brought by indirect resellers. Sandoz did not admit to any wrongdoing.
The agreement marks the latest settlement in a long-running battle between numerous states and many of the largest players in the generic drug industry, which were accused of fixing prices for their medicines. Previously, Glenmark Pharmaceuticals, Lannett, Bausch, Apotex, and Heritage Pharmaceuticals collectively settled lawsuits for nearly $98 million.
Illinois’ financial crisis could bring the state to a halt
The final 6 ‘Game of Thrones’ episodes might feel like a full season
New Season 8 Walking Dead trailer flashes forward in time
Mod turns ‘Counter-Strike’ into a ‘Tekken’ clone with fighting chickens
Meet Superman’s grandfather in new trailer for Krypton
Disney’s live-action Aladdin finally finds its stars
STAT+: Is there a pharma mega-merger in the making?
BioNTech picks Sobi CEO Oelkers to lead as founders plot new mRNA biotech
STAT+: Sandoz to pay $478.5 million to settle price-fixing allegations in long-running battle with states
Novo’s late-stage IL-6 stumble shakes inflammation space
STAT+: BioNTech names Guido Oelkers its new CEO
‘Unlikely’ AstraZeneca-BMS mega-merger would be largest pharma deal ever
Illinois’ financial crisis could bring the state to a halt
The final 6 ‘Game of Thrones’ episodes might feel like a full season
New Season 8 Walking Dead trailer flashes forward in time
Mod turns ‘Counter-Strike’ into a ‘Tekken’ clone with fighting chickens
Meet Superman’s grandfather in new trailer for Krypton
Disney’s live-action Aladdin finally finds its stars
-
Fierce Biotech4 months ago
Scientists turn pig semen extract into eye drops that kill cancer in mice
-
Uncategorized9 years agoThese ’90s fashion trends are making a comeback in 2017
-
Endpoints News5 months ago
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
-
Uncategorized4 months agoNovartis buys Synnovation’s PI3Kα inhibitors for $3 billion
-
Uncategorized9 years ago
According to Dior Couture, this taboo fashion accessory is back
-
Uncategorized9 years ago
Phillies’ Aaron Altherr makes mind-boggling barehanded play
-
Uncategorized9 years ago
Steph Curry finally got the contract he deserves from the Warriors
-
Uncategorized9 years ago
Uber and Lyft are finally available in all of New York State